Product-specific evidence
Tesamorelin: approved uses, formulation, and monitoring questions
Understand tesamorelin and EGRIFTA, HIV-associated lipodystrophy, why the approved product is not indicated for general weight-loss management, and monitoring questions.
What should I know about Tesamorelin?
Tesamorelin is a growth hormone-releasing factor analog. EGRIFTA products have a specific indication involving excess abdominal fat in adults with HIV-associated lipodystrophy; the labeling states they are not indicated for weight-loss management. That evidence should not be generalized to every body-composition goal or compounded preparation.
Explore the guides
Tesamorelin and EGRIFTA: Approved Use vs. General Weight Loss
EGRIFTA WR contains tesamorelin and is indicated for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Its label states that it is not indicated for weight-loss management.
Read guideTesamorelin Monitoring: Questions About IGF-1 and Glucose
Tesamorelin product labeling addresses increased IGF-1 and the risk of glucose intolerance or diabetes. Before treatment, ask the clinician how relevant history, baseline findings, follow-up, and symptoms will inform an individualized plan.
Read guideEGRIFTA WR, EGRIFTA SV, and Compounded Tesamorelin: Formulation Matters
EGRIFTA WR and EGRIFTA SV have different product-specific doses, preparation steps, and storage instructions; the WR label states that they are not substitutable. A compounded tesamorelin preparation is another distinct product question.
Read guideCommon Tesamorelin questions
Is tesamorelin a general weight-loss drug?
The EGRIFTA WR labeling states that it is not indicated for weight-loss management. Its approved indication is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. That is a specific clinical context.
Are all tesamorelin formulations interchangeable?
No. EGRIFTA WR and other formulations have product-specific instructions. The WR label explicitly directs readers to separate instructions for another formulation. Do not transfer preparation or administration directions between products.
What monitoring questions should I ask?
Ask how the care team evaluates relevant medical history and monitors issues such as IGF-1 and glucose, as appropriate to the prescribed product and your circumstances. Use the product's current labeling and clinician's plan.
Is compounded tesamorelin the same as EGRIFTA?
A compounded preparation is not an FDA-approved generic or automatically equivalent to an approved EGRIFTA product. Ask why the proposed formulation is appropriate, what evidence applies, and which instructions govern it.
Prepare for the next conversation
Use the consultation checklist and cost worksheet to organize your questions. A licensed clinician must determine whether a specific treatment is appropriate.
Primary sources
By the PacificRx editorial team. Educational information, not individualized medical advice.